Apyx Medical Corp APYX
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
-0.11
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $52.8M | -$11.2M | $33.0M | -$9.1M | $14.8M |
| 2024 | $48.1M | -$23.5M | $29.4M | -$18.8M | $14.3M |
| 2023 | $52.3M | -$18.7M | $33.8M | -$5.8M | $26.9M |
| 2022 | $44.5M | -$23.2M | $29.1M | -$21.3M | $37.8M |
| 2021 | $48.5M | -$15.2M | $33.6M | -$11.2M | $54.0M |
| 2020 | $27.7M | -$11.9M | $17.5M | -$16.6M | $63.9M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.11 (distress)
- Working capital / assets 0.7
- Retained earnings / assets -1.333
- EBIT / assets -0.096
- Equity / liabilities 0.285
Source: SEC EDGAR filings · CIK 0000719135 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.